Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

China Cord Blood Corp (CO): A Steady Growth Outlook Is Not Fully Reflected in This Company’s Share Price

Page 1 of 2

China Cord Blood Corp (NYSE:COoperates stem cell storage facilities in China and has delivered strong growth over the past year. However, the stock price has not reflected this growth. KKR & Co. L.P. (NYSE:KKR) took a 24% stake in China Cord Blood Corp (NYSE:CO) for $270 million last year and could look to increase the size of its ownership position in the company or engage in a buyout.

China Cord Blood Corp (NYSE:CO) engages in the provision of umbilical cord blood storage and other related services in China. It conducts cord blood testing, processing and storage. It does lab testing, hematopoietic stem cell processing, and storage of stem cells. The company tests, processes, and stores cord blood and also provides a matching service. Its cord blood banks are located in Beijing, Guangdong, and Zhejiang provinces.

Trends are positive for long-term growth

The stem cell storage industry is still relatively small in China. Stem cells have the potential to treat immune and blood disorders as well as certain cancers. Only around 1% of births utilize storage services from a company like China Cord Blood Corp (NYSE:CO), whereas in Hong Kong, 15% use this service and 22% in Taiwan. As the average Chinese consumer’s disposable income rises, utilization of stem cell storage should rise and start to reflect levels in wealthier parts of the region. In addition, the one child policy in China can also help drive industry growth with increased importance and spending focus on a single child. Stem cell storage is a more likely use of an incremental disposable income because of the one child policy.

Cord Blood is currently working to secure licenses in three additional provinces in China to expand its geographic footprint. This would accelerate already strong revenue and earnings growth at the firm. Revenue increased 12% in 2012. It is also very noteworthy that it has exclusive rights to the Chinese provinces where it already operates.

Analyst estimates currently reflect flat earnings growth in FY13 and FY14. The company did benefit from a Dragon Year boom in babies that led to above average subscriber growth for its services. Management expects subscriber growth to decline now in the year of the Snake. Revenue is expected to increase by about 25% in FY13 and close to 10% in FY14 according to analyst estimates.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!